These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7861833)

  • 21. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A co-operative study on prophylactic effect of oral administration of high-dose amphotericin B syrup for systemic fungal infection in patients with hematological neoplasms. Chugoku-Shikoku Study Group of Mycosis with Hematologic Disease].
    Kimura I; Kuramoto J; Yahata Y; Irino S; Takahashi I; Sezaki T; Tsubota T; Watanabe Y; Hara M; Hino N
    Gan To Kagaku Ryoho; 1990 May; 17(5):1027-32. PubMed ID: 2185693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Reconstitution of peripheral blood lymphocytes in patients treated with bone marrow transplantation: comparison between allogeneic and autologous transplantation].
    Parra C; Roldán E; Rodríguez C; Pérez de Oteyza J; Oteho E; López J; Maldonado MS; García Laraña J; Muñoz A; Odriozola J; Brieva JA
    Med Clin (Barc); 1999 Jun; 113(1):1-5. PubMed ID: 10422068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
    Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
    Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early infections in patients undergoing bone marrow or blood stem cell transplantation--a 7 year single centre investigation of 409 cases.
    Krüger W; Rüssmann B; Kröger N; Salomon C; Ekopf N; Elsner HA; Kaulfers PM; Mack D; Fuchs N; Dürken M; Kabisch H; Erttmann R; Zander AR
    Bone Marrow Transplant; 1999 Mar; 23(6):589-97. PubMed ID: 10217190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
    Wingard JR
    Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of recombinant human granulocyte colony-stimulating factor in children undergoing bone marrow transplantation.
    Dini G; Floris R; Pession A; Manfredini L; Dallorso S; Lanino E; Garaventa A; Miano M; Kotitsa Z; Rondelli R
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():121-8. PubMed ID: 8932813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
    Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
    Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts.
    Wimperis JZ; Baglin TP; Marcus RE; Warren RE
    Bone Marrow Transplant; 1991 Nov; 8(5):363-7. PubMed ID: 1768971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions.
    Nicholl TA; Nimmo CR; Shepherd JD; Phillips P; Jewesson PJ
    Ann Pharmacother; 1995 Nov; 29(11):1081-7. PubMed ID: 8573948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
    Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
    Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
    Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Szer J; Durrant S; Schwarer AP; Bradstock KF; Gibson J; Arthur C; To LB; Hughes T; Raunow H
    Intern Med J; 2004 Mar; 34(3):98-101. PubMed ID: 15030456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients.
    Riley DK; Pavia AT; Beatty PG; Petersen FB; Spruance JL; Stokes R; Evans TG
    Am J Med; 1994 Dec; 97(6):509-14. PubMed ID: 7985709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation.
    Krüger W; Stockschläder M; Sobottka I; Betker R; De Wit M; Kröger N; Grimm J; Arland M; Fiedler W; Erttmann R; Zander AR
    Leuk Lymphoma; 1997 Feb; 24(5-6):491-9. PubMed ID: 9086439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients.
    Karthaus M; Doellmann T; Klimasch T; Elser C; Rosenthal C; Ganser A; Heil G
    Chemotherapy; 2000; 46(4):293-302. PubMed ID: 10859435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylaxis of infection in bone marrow transplants.
    Winston DJ; Ho WG; Gale RP; Champlin RE
    Eur J Cancer Clin Oncol; 1988; 24 Suppl 1():S15-23. PubMed ID: 3127217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.